PMID- 20371915
OWN - NLM
STAT- MEDLINE
DCOM- 20100730
LR  - 20201226
IS  - 1735-1383 (Print)
IS  - 1735-1383 (Linking)
VI  - 7
IP  - 1
DP  - 2010 Mar
TI  - KIR2DS3 is associated with protection against acute myeloid leukemia.
PG  - 8-17
AB  - BACKGROUND: Interaction between killer cell immunoglobulin-like receptors (KIR) 
      and human leukocyte antigen (HLA) class I molecules is important for regulation 
      of natural killer (NK) cell function. OBJECTIVE: The aim of this study was to 
      investigate the impact of compound KIR-HLA genotype on susceptibility to acute 
      leukemia. METHODS: Cohorts of Iranian patients with acute myeloid leukemia (AML; 
      n=40) and acute lymphoid leukemia (ALL; n=38) were genotyped for seventeen KIR 
      genes and their three major HLA class I ligand groups (C1, C2, Bw4) by a combined 
      polymerase chain reaction-sequence-specific primers (PCR-SSP) assay. The results 
      were compared with those of 200 healthy control individuals. RESULTS: We found a 
      significantly decreased frequency of KIR2DS3 in AML patients compared to control 
      group (12.5% vs. 38%, odds ratio=0.23, p=0.0018). Also, the KIR3DS1 was less 
      common in AML group than controls (27.5% vs. 44.5%, p=0.0465, not significant 
      after correction). Other analyses including KIR genotypes, distribution and 
      balance of inhibitory and activating KIR+HLA combinations, and co-inheritance of 
      activating KIR genes with inhibitory KIR+HLA pairs were not significantly 
      different between leukemia patients and the control group. However, in AML 
      patients a trend toward less activating and more inhibitory KIR-HLA state was 
      observed. Interestingly, this situation was not found in ALL patients and 
      inhibition enhancement through increase of HLA ligands and inhibitory 
      combinations was the main feature in this group. CONCLUSION: Our findings may 
      suggest a mechanism for escape of leukemic cells from NK cell immunity.
FAU - Shahsavar, Farhad
AU  - Shahsavar F
AD  - Division of Transplant Immunology and Immunogenetics, Department of Immunology, 
      Iran University of Medical Sciences, Tehran, Iran.
FAU - Tajik, Nader
AU  - Tajik N
FAU - Entezami, Kobra-Zinat
AU  - Entezami KZ
FAU - Fallah Radjabzadeh, Masoomeh
AU  - Fallah Radjabzadeh M
FAU - Asadifar, Behnam
AU  - Asadifar B
FAU - Alimoghaddam, Kamran
AU  - Alimoghaddam K
FAU - Ostadali Dahaghi, Mohammadreza
AU  - Ostadali Dahaghi M
FAU - Jalali, Arash
AU  - Jalali A
FAU - Ghashghaie, Andisheh
AU  - Ghashghaie A
FAU - Ghavamzadeh, Ardeshir
AU  - Ghavamzadeh A
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Immunol
JT  - Iranian journal of immunology : IJI
JID - 101282932
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (KIR2DS3 protein, human)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Genotype
MH  - Histocompatibility Antigens Class I/genetics/immunology
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Leukemia, Myeloid, Acute/*genetics/*immunology
MH  - Ligands
MH  - Male
MH  - Middle Aged
MH  - Receptors, KIR/*genetics/*immunology
MH  - Tumor Escape/genetics/immunology
EDAT- 2010/04/08 06:00
MHDA- 2010/07/31 06:00
CRDT- 2010/04/08 06:00
PHST- 2010/04/08 06:00 [entrez]
PHST- 2010/04/08 06:00 [pubmed]
PHST- 2010/07/31 06:00 [medline]
AID - 02 [pii]
PST - ppublish
SO  - Iran J Immunol. 2010 Mar;7(1):8-17.